Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00143455
Status:
COMPLETED
Last Update Posted:
2010-02-18
First Post:
2005-09-01
Brief Title:
Study Of Irinotecan Hydrochloride CamptoR And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Open Label Randomised Multicentre Phase III Study Of Irinotecan Hydrochloride Campto Registered And Cisplatin Versus Etoposide And Cisplatin In Chemotherapy Naive Patients With Extensive Disease - Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2010-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To compare the effects of irinotecan hydrochloride with cisplatin to the standard regimen etoposide plus cisplatin on overall survival in chemotherapy-naive patients with newly diagnosed Extensive Disease-Small Cell Lung Cancer ED-SCLC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None